Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ecam/volume-2016/5929525/figures/5929525.fig.002a.svgz" name="5929525.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>CTL response rate</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ecam/volume-2016/5929525/figures/5929525.fig.002b.svgz" name="5929525.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Rate of positive wells</td></tr></table>

<div>CTL response: CTL responses to the vaccinated peptides in prevaccination PBMCs and in postvaccination (at the end of the first cycle) are shown. (a) Percentage of positive CTL responses among patients tested. (b) Percentage of positive wells among total wells tested.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer 

Figure 2 | Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer 